View in EDS

Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).

Saved in:
Bibliographic Details
Title: Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).
Authors: Battaglin F; USC Norris Cancer Center, Los Angeles, CA, United States., O'Neil BH; University Hospital Grosshadern, Munich, Germany., Stintzing S; Department of Hematology, Oncology, and Cancer Immunology (CCM); Charité - Universitaetsmedizin Berlin, Berlin, Germany; DKTK Heidelberg, Partner Site, Berlin, Germany. Electronic address: Sebastian.stintzing@charite.de., Ou FS; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, United States., Zemla TJ; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, United States., Niedzwiecki D; Department of Biostatistics and Bioinformatics and Duke Cancer Institute-Biostatistics, Duke University, Durham, NC, United States., Innocenti F; UNC Lineberger Cancer Center, Chapel Hill, NC, United States., Hochster HS; Yale Cancer Center, New Haven, CT, United States., von Weikersthal LF; MVZ Gesundheitszentrum St. Marien GmbH, Amberg, Germany., Decker T; Onkologie Ravensburg, Ravensburg, Germany., Kiani A; Department of Medicine IV, Klinikum Bayreuth GmbH, Bayreuth, Germany., Vehling-Kaiser U; VK&K Studienzentrum, Landshut, Germany., Heintges T; Department of Medicine II, Städtisches Klinikum, Neuss, Germany., Lerchenmüller C; Oncological Practice, Münster, Germany., Weiss L; Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany., Heinrich K; Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany., Goldberg RM; West Virginia University Cancer Institute, Morgantown, WV, United States., Mayer RJ; Dana Farber Cancer Center, Boston MA, United States., Schilsky RL; University of Chicago, Chicago IL, United States., Blanke CD; Oregon Health Sciences, Portland, OR, United States., Venook AP; UCSF Helen Diller Cancer Center, San Francisco, CA, United States., Lenz HJ; USC Norris Cancer Center, Los Angeles, CA, United States., Heinemann V; Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany.
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Sep 09; Vol. 227, pp. 115694. Date of Electronic Publication: 2025 Aug 05.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40803104
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Battaglin+F%22">Battaglin F</searchLink>; USC Norris Cancer Center, Los Angeles, CA, United States.<br /><searchLink fieldCode="AU" term="%22O'Neil+BH%22">O'Neil BH</searchLink>; University Hospital Grosshadern, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Stintzing+S%22">Stintzing S</searchLink>; Department of Hematology, Oncology, and Cancer Immunology (CCM); Charité - Universitaetsmedizin Berlin, Berlin, Germany; DKTK Heidelberg, Partner Site, Berlin, Germany. Electronic address: Sebastian.stintzing@charite.de.<br /><searchLink fieldCode="AU" term="%22Ou+FS%22">Ou FS</searchLink>; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, United States.<br /><searchLink fieldCode="AU" term="%22Zemla+TJ%22">Zemla TJ</searchLink>; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, United States.<br /><searchLink fieldCode="AU" term="%22Niedzwiecki+D%22">Niedzwiecki D</searchLink>; Department of Biostatistics and Bioinformatics and Duke Cancer Institute-Biostatistics, Duke University, Durham, NC, United States.<br /><searchLink fieldCode="AU" term="%22Innocenti+F%22">Innocenti F</searchLink>; UNC Lineberger Cancer Center, Chapel Hill, NC, United States.<br /><searchLink fieldCode="AU" term="%22Hochster+HS%22">Hochster HS</searchLink>; Yale Cancer Center, New Haven, CT, United States.<br /><searchLink fieldCode="AU" term="%22von+Weikersthal+LF%22">von Weikersthal LF</searchLink>; MVZ Gesundheitszentrum St. Marien GmbH, Amberg, Germany.<br /><searchLink fieldCode="AU" term="%22Decker+T%22">Decker T</searchLink>; Onkologie Ravensburg, Ravensburg, Germany.<br /><searchLink fieldCode="AU" term="%22Kiani+A%22">Kiani A</searchLink>; Department of Medicine IV, Klinikum Bayreuth GmbH, Bayreuth, Germany.<br /><searchLink fieldCode="AU" term="%22Vehling-Kaiser+U%22">Vehling-Kaiser U</searchLink>; VK&K Studienzentrum, Landshut, Germany.<br /><searchLink fieldCode="AU" term="%22Heintges+T%22">Heintges T</searchLink>; Department of Medicine II, Städtisches Klinikum, Neuss, Germany.<br /><searchLink fieldCode="AU" term="%22Lerchenmüller+C%22">Lerchenmüller C</searchLink>; Oncological Practice, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Weiss+L%22">Weiss L</searchLink>; Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Heinrich+K%22">Heinrich K</searchLink>; Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Goldberg+RM%22">Goldberg RM</searchLink>; West Virginia University Cancer Institute, Morgantown, WV, United States.<br /><searchLink fieldCode="AU" term="%22Mayer+RJ%22">Mayer RJ</searchLink>; Dana Farber Cancer Center, Boston MA, United States.<br /><searchLink fieldCode="AU" term="%22Schilsky+RL%22">Schilsky RL</searchLink>; University of Chicago, Chicago IL, United States.<br /><searchLink fieldCode="AU" term="%22Blanke+CD%22">Blanke CD</searchLink>; Oregon Health Sciences, Portland, OR, United States.<br /><searchLink fieldCode="AU" term="%22Venook+AP%22">Venook AP</searchLink>; UCSF Helen Diller Cancer Center, San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Lenz+HJ%22">Lenz HJ</searchLink>; USC Norris Cancer Center, Los Angeles, CA, United States.<br /><searchLink fieldCode="AU" term="%22Heinemann+V%22">Heinemann V</searchLink>; Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229005373%22">European journal of cancer (Oxford, England : 1990)</searchLink> [Eur J Cancer] 2025 Sep 09; Vol. 227, pp. 115694. <i>Date of Electronic Publication: </i>2025 Aug 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science+Ltd%22">Elsevier Science Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9005373 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1879-0852 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209598049%22">09598049 </searchLink><i>NLM ISO Abbreviation: </i>Eur J Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40803104
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ejca.2025.115694
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 115694
    Titles:
      – TitleFull: Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Battaglin F
      – PersonEntity:
          Name:
            NameFull: O'Neil BH
      – PersonEntity:
          Name:
            NameFull: Stintzing S
      – PersonEntity:
          Name:
            NameFull: Ou FS
      – PersonEntity:
          Name:
            NameFull: Zemla TJ
      – PersonEntity:
          Name:
            NameFull: Niedzwiecki D
      – PersonEntity:
          Name:
            NameFull: Innocenti F
      – PersonEntity:
          Name:
            NameFull: Hochster HS
      – PersonEntity:
          Name:
            NameFull: von Weikersthal LF
      – PersonEntity:
          Name:
            NameFull: Decker T
      – PersonEntity:
          Name:
            NameFull: Kiani A
      – PersonEntity:
          Name:
            NameFull: Vehling-Kaiser U
      – PersonEntity:
          Name:
            NameFull: Heintges T
      – PersonEntity:
          Name:
            NameFull: Lerchenmüller C
      – PersonEntity:
          Name:
            NameFull: Weiss L
      – PersonEntity:
          Name:
            NameFull: Heinrich K
      – PersonEntity:
          Name:
            NameFull: Goldberg RM
      – PersonEntity:
          Name:
            NameFull: Mayer RJ
      – PersonEntity:
          Name:
            NameFull: Schilsky RL
      – PersonEntity:
          Name:
            NameFull: Blanke CD
      – PersonEntity:
          Name:
            NameFull: Venook AP
      – PersonEntity:
          Name:
            NameFull: Lenz HJ
      – PersonEntity:
          Name:
            NameFull: Heinemann V
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 09
              Text: 2025 Sep 09
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1879-0852
          Numbering:
            – Type: volume
              Value: 227
          Titles:
            – TitleFull: European journal of cancer (Oxford, England : 1990)
              Type: main
ResultId 1